



ALNYLAM PHARMACEUTICALS UK 2018 PATIENT ORGANIZATION SUPPORT

Alnylam Pharmaceuticals UK has voluntarily agreed to abide by the PMCPA Code of Practice and supports the efforts of the ABPI to increase transparency in the pharmaceutical industry.

In accordance with Clause 27 of the PMCPA Code of Practice for the Pharmaceutical Industry, this document lists UK patient organizations to which Alnylam provided support to in 2018.

For financial support, the date of payment has been used to determine the year in which support will be declared (e.g., if an agreement was signed in December 2018 but the payment for this agreement was made in January 2019, the support will be declared as having taken place in 2019 in the disclosure that will be made in 2020).

Amyloidosis Research Consortium UK

- In 2018, a grant of £105,000 was made to support the Amyloidosis Research Consortium (ARC) UK's activities across Europe including education and awareness programs and market access and health services research programs

Cardiomyopathy UK

- In 2018, Alnylam provided sponsorship of £3,961 to Cardiomyopathy UK to support 2 educational meetings that aimed to educate clinicians on cardiomyopathy

British Porphyria Association

- In 2018, Alnylam:
 - Made a charitable donation of \$7827. This was money raised from an internal Alnylam charitable auction
 - Paid a BPA representative a £400 honorarium for them to participate in an advisory panel and reimbursed £45.45 for transportation expenses